Live Chat

Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
date Close change Change (%) Open High Low

Latest news

Frances Wang 2024 Dec 29, 16:00

Stock market today: Most Asian stocks fell after US equities declined

Stocks
Frances Wang 2024 Dec 29, 16:00

MicroStrategy joins Nasdaq-100 index: MSTR stock performance analysis 2024

Cryptocurrencies Stocks
Dyogenes Diniz 2024 Dec 29, 16:00

Morning Note: Key Levels & Data Driving the Last Monday of 2024

Forex Morning Note USD
Closing 2024
Dyogenes Diniz 2024 Dec 26, 17:00

Week ahead: Closing 2024 and First Economic data from 2025

Forex Indices
Tesla soars
Dyogenes Diniz 2024 Dec 26, 17:00

Morning Note: Tesla Soars, AUDUSD Hits Key Support, Oil & SP500 Insights

Forex Oil S&P 500
Frances Wang 2024 Dec 26, 16:00

Nikkei 225 up 1.39%: Japanese Stocks Rise Following Yen's Continued Weakness

Stocks
Frances Wang 2024 Dec 25, 16:00

Asian stock market today: most Asian stocks rise amid thin holiday trading

Stocks
Frances Wang 2024 Dec 25, 16:00

Stock market today: Nasdaq, S&P 500, Dow surge ahead of Christmas break

Stocks

Info

Spread

0.06

Spread (%)

0.8186 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Market open

Monday

14:31 - 20:59

Tuesday

14:31-20:59

Thursday

14:31-20:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

1028079808

Shares Outstanding

137720000

Earnings Date (Next)

0000-00-00

instr__dividend_date

instr__ex_dividend_date

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

EPS

-3.93

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments
Trustpilot
Live Chat